Eli Lilly Benelux

Brussel ·KBO/BCE: BE 0406.754.454

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	nothing on record	not filed	-
31-12-2024	31-07-2025	29-07-2025	2 d early	2025-00329072
31-12-2023	31-07-2024	19-07-2024	12 d early	2024-00275198
31-12-2022	31-07-2023	27-07-2023	4 d early	2023-00278712
31-12-2021	31-07-2022	26-07-2022	5 d early	2022-20223792
31-12-2020	31-07-2021	20-07-2021	11 d early	2021-37900138
31-12-2019	31-07-2020	25-08-2020	25 d late	2020-44700043
31-12-2018	31-07-2019	08-07-2019	23 d early	2019-31700095
31-12-2017	31-07-2018	04-07-2018	27 d early	2018-29800094
31-12-2016	31-07-2017	20-07-2017	11 d early	2017-34400176
31-12-2015	31-07-2016	14-07-2016	17 d early	2016-32300504

Metric	This company	Sector median	Position in the sector
Solvency	38.8%	31.0%	better than 58% of 548 sector peers
Net result	€6.09M	€47k	better than 95% of 548 sector peers
Equity	€19.95M	€469k	better than 94% of 549 sector peers
Staff costs	€24.82M	€494k	higher than 95% of 404 sector peers
Employees (FTE)	86.9	7.5	better than 93% of 359 sector peers

Line item	Code	2024
Balance sheet, Assets
TOTAL ASSETS	20/58	€51.44M
Fixed assets	21/28	€253k
Tangible fixed assets	22/27	€252k
Financial fixed assets	28	€1k
Current assets	29/58	€51.19M
Amounts receivable within one year	40/41	€50.89M
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€51.44M
Equity	10/15	€19.95M
Contributions / capital	10/11	€12.89M
Reserves	13	€6.91M
Accumulated profits (losses)	14	€141k
Amounts payable	17/49	€31.50M
Amounts payable within one year	42/48	€31.50M
Trade debts payable within one year	44	€15.84M
Income statement
Turnover	70	€142.73M
Operating result	9901	€7.87M
Financial income	75	€554k
Financial charges	65	€8k
Result before taxes	9903	€8.42M
Income taxes	67/77	€2.33M
Net result for the period	9904	€6.09M
Result to be appropriated	9905	€6.09M

Summary

Statutory auditor	IRE/IBR number	Tenure
EY Réviseurs d'Entreprises SRLCurrent Commissaire	-	18-09-2025 → present
Carlo-Sébastien d'Addario Commissaire succeeded by EY Réviseurs d'Entreprises SRL in 2025	-	13-09-2022 → 18-09-2025
Ernst & Young Réviseurs d'Entreprises SC SCRL Commissaire succeeded by Carlo-Sébastien d'Addario in 2022	-	24-01-2020 → 13-09-2022

NACE primary	Groothandel in farmaceutische en medische artikelen(46460)
Legal form	Public limited company(014)
Incorporation	19-06-1969
Status	Active
Postal code	1000